Why Is Neurocrine Biosciences Stock Trading Lower Today?
Thursday, Neurocrine Biosciences Inc NBIX released Phase 2 study results from two signal-seeking pipeline programs in focal onset seizures and anhedonia. The investigational selective NaV 1.6 inhibitor, NBI-921352, licensed from Xenon Pharmaceuticals Inc XENE, failed to demonstrate meaningful…
#phase2 #anhedonia #nav #nbi921352 #xene #fos #neurocrine #takeda #nbi1065845 #nbi1070770